Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

ceptin SC (trastuzumab subcutaneous) at the European Society for Medical Oncology meeting in Milan on October 9. The results showed that the 8mg/kg dose of SC trastuzumab resulted in area under the curve results comparable to the approved 6 mg/kg IV dose. In addition, the SC formulation was well tolerated with fewer adverse events observed in the SC groups compared to IV controls.  

Third Quarter 2010 Financial ResultsThe net loss for the third quarter of 2010 was $12.4 million, or $0.13 per share, compared with a net loss for the third quarter of 2009 of $13.9 million, or $0.16 per share.

  • Revenue for the third quarter of 2010 was $3.4 million, compared to $3.0 million for the third quarter of 2009. Revenues under collaborative agreements for the third quarter of 2010 were $3.3 million, compared to $2.6 million for the third quarter of 2009. Revenues under collaborative agreements in the third quarter 2010 primarily consisted of the amortization of upfront fees received from Baxter and Roche of $695,000 and research and development reimbursements from Baxter and Roche of $2.5 million.
  • Research and development expenses for the third quarter of 2010 were $12.4 million, compared with $13.2 million for the third quarter of 2009, primarily due to a decrease in clinical trial expenses mainly related to the Ultrafast Insulin program.  
  • Selling, general and administrative expenses for the third quarter of 2010 were $3.4 million, compared to $3.7 million for the third quarter of 2009, due to a decrease in market research expenses.  
  • Cash and cash equivalents were $89.8 million as of September 30, 2010, compared with $67.5 million as of December 31, 2009 and $77.6 million as of September 30, 2009. Net cash burn for the third quarter of 2010, excluding the proceeds from the financing completed in September 2010, was approximately $11.4 million. Net cash burn for the first nine months of 2010, excluding the proceed
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
    (Date:5/21/2015)... 2015 Patent Offering, The patent’s technology ... or therapeutic imaging within a body lumen (open space). ... having a low cost, single-use disposable illumination and camera ... October 18, 2013 and the patent approval was received ... physician to customize the lighting and magnification of the ...
    (Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
    (Date:5/21/2015)... 21, 2015 Tunnell Consulting, ... firm as senior statistician and Principal, a position to ... in the management and analysis of complex and large ... industries. , “We’re delighted to have Julia join the ... analytics,” said Dr. Philippe Cini, Group Vice President and ...
    Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
    ... VIEW, Calif., Jan. 30 /PRNewswire/ -- ... genome sequencing company, today announced that it will release ... the 10th annual Advances in Genome Biology and Technology ... from Feb. 4-7.Dr. Clifford Reid, chairman, president and CEO ...
    ... announced today that it intends to commence a cash tender ... 86.50 per share. Roche, which currently owns 55.8% of the ... approximately two weeks. The offer replaces the public proposal made ... the publicly-held shares of Genentech at a price of US$ ...
    ... Basic Sciences award in this inaugural edition of the ... by physicists Peter Zoller (Austria, 1952) and Ignacio Cirac ... science", in the words of the jury chaired by ... Cirac,s research is opening up vital new avenues for ...
    Cached Biology Technology:Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 2Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 3Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 4Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 5Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation 2
    (Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
    (Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
    (Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
    Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
    ... Tactile Sensors at Your Fingertips, Literally, ... Systems, Inc.,(PPS) today announces their innovative new ... immediate sale worldwide. FingerTPS,sensors are soft, flexible ... accurate,repeatable tactile force data to a PC ...
    ... the mastermind behind a project that has led to an ... on an endangered species of ape. Ursula Goodenough, ... driving force behind I,m Lucy, A Day in the ... Goodenough,s daughter, and featuring the photographs of St. Louisan Marian ...
    ... a staggering number of cells perform a feat that still ... replicas of each other. The process is called mitosis, and ... of cancer. Little is known about the ... Chase Cancer Center and Technion-Israel Institute of Technology in Haifa, ...
    Cached Biology News:Wearable Sensors Conceived at Harvard Robotics Lab Measure Hand Forces 2Book's plea: Save the bonobos 2Book's plea: Save the bonobos 3Book's plea: Save the bonobos 4Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 3
    NATIVE PORCINE COLIPASE...
    Polyclonal Antibody to CRTR-1...
    Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
    Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
    Biology Products: